Article: Management of Lead Encephalopathy with DMSA After Exposure to Lead-Contaminated Moonshine

Background: Lead encephalopathy is a severe manifestation of lead poisoning that can present with altered mental status and seizures and has been associated with illicit moonshine consumption. Lead encephalopathy has traditionally been treated using dimercaprol (British anti-Lewisite, BAL) and calcium disodium ethylenediaminetetraacetic acid (CaNa2EDTA).

Case Report: We describe a patient with lead encephalopathy related to lead-contaminated moonshine consumption, who was treated using dimercaptosuccinic acid (DMSA) due to a national shortage of CaNa2EDTA. A 66-year-old woman presented to a hospital with headache, irritability, and altered mental status. On hospital day 16, she was found to have a whole blood lead concentration of 148.2 μg/dL and a 24-h urine lead concentration of 232 μg/day. Due to a national shortage of CaNa2EDTA, the patient was given one dose of BAL and then started on DMSA via nasogastric tube. She dramatically improved over 4 days and was subsequently transitioned to oral DMSA and outpatient treatment. One day prior to discharge, her whole blood lead concentration was 47.2 μg/dL and her mental status was normal. DMSA was used in lieu of CaNa2EDTA to treat the patient with lead encephalopathy. The patient subsequently experienced clinical improvement and declining whole blood level concentrations.

Conclusion: Further prospective studies are needed to compare the efficacy of DMSA versus CaNa2EDTA in patients with lead encephalopathy.

Citing Articles

Trends in Shortages of Lead Chelators From 2001 to 2022.

Whitledge J, Soto P, Glowacki K, Calello D, Fox E, Mazer-Amirshahi M J Pediatr Pharmacol Ther. 2024; 29(3):306-315.

PMID: 38863853 PMC: 11163907. DOI: 10.5863/1551-6776-29.3.306.

A Case of Severe Lead Encephalopathy with Cardiac Arrest Managed During a Chelation Shortage.

Idowu D, Gray Z, Stanton M, Rushton W, Gummin D J Med Toxicol. 2023; 20(1):49-53.

PMID: 37843802 PMC: 10774239. DOI: 10.1007/s13181-023-00970-2.

Potential diagnostic biomarkers for lead-induced hepatotoxicity and the role of synthetic chelators and bioactive compounds.

Lakka N, Pai B, Mani M, Dsouza H Toxicol Res (Camb). 2023; 12(2):178-188.

PMID: 37125327 PMC: 10141777. DOI: 10.1093/toxres/tfad014.

Biomimetic Antidote Nanoparticles: a Novel Strategy for Chronic Heavy Metal Poisoning.

Wang H, Yao Q, Zhu W, Yang Y, Gao C, Han C AAPS PharmSciTech. 2022; 24(1):12.

PMID: 36451071 DOI: 10.1208/s12249-022-02466-8.

In vitro activity of EDTA and TOL-463 against Neisseria gonorrhoeae.

Nash E, Henning T, Pham C, Pettus K, Sharpe S, Kersh E Diagn Microbiol Infect Dis. 2018; 93(4):369-371.

PMID: 30552033 PMC: 6519449. DOI: 10.1016/j.diagmicrobio.2018.10.021.

References

1.

Morgan B, Parramore C, Ethridge M . Lead contaminated moonshine: a report of Bureau of Alcohol, Tobacco and Firearms analyzed samples. Vet Hum Toxicol. 2004; 46(2):89-90. View

2.

CHISOLM Jr J . The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediatr. 1968; 73(1):1-38. DOI: 10.1016/s0022-3476(68)80036-8. View

3.

Fournier L, Thomas G, Garnier R, Buisine A, Houze P, Pradier F . 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol Adverse Drug Exp. 1988; 3(6):499-504. DOI: 10.1007/BF03259898. View

4.

Mann K, Travers J . Succimer, an oral lead chelator. Clin Pharm. 1991; 10(12):914-22. View

5.

FOREMAN H, TRUJILLO T . The metabolism of C14 labeled ethylenediaminetetraacetic acid in human beings. J Lab Clin Med. 1954; 43(4):566-71. View